However, in this study, only LXRα was demonstrated to affect the level of SOCS3, indicating that the LXRα-mediated induction of SOCS3 is responsible for the anti-HCC effects of LXR agonists even though LXRβ has the function of anti-cancer [45]. The gene discussed is SOCS3; the disease is cancer.